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ABSTRACT 3 
Thalidomide remains notorious as a result of the damage it caused to children born 4 
to mothers who used it to treat morning sickness between 1957 and 1961. The re-5 
emergence of the drug to treat a range of conditions including erythema nodosum 6 
leprosum (a complication of leprosy) has led to a new generation of thalidomide 7 
damaged children being born in Brazil. Although thalidomide affects most of the 8 
developing tissues and organs of the body, the damage to the limbs is striking. 9 
Indeed phocomelia, the severe reduction or loss of the proximal long bones with 10 
retention of the distal hand/foot plate remains the stereotypical image of thalidomide. 11 
This review focuses on the type and range of damage thalidomide caused to the 12 
limbs, reviews current understanding of the mechanisms underlying thalidomide-13 
induced limb malformations and outlines some of the challenges remaining in 14 
elucidating its teratogenicity.  15 
 16 
Level of evidence criteria: Not applicable as this is a scientific review, could also be 17 
classified as Level V. 18 
  19 
 3 
 20 
THALIDOMIDE – A BRIEF HISTORY 21 
Thalidomide was marketed in 1957 by Chemie-Grunenthal as a non-addictive, non-22 
toxic, non-barbiturate sedative. It was very popular at the time, being distributed in at 23 
least 46 countries worldwide as an effective drug in relieving morning sickness. 24 
Despite its effectiveness, thalidomide use was associated with peripheral neuropathy 25 
in patients and for this reason, Frances Kelsey, a reviewer for the United States 26 
Food and Drug Administration (US FDA) refused to licence its distribution in the US 27 
(Vargesson, 2015). Subsequently, there were growing suggestions around 1960 that 28 
thalidomide use was the cause of an epidemic of severe birth defects in the UK, 29 
Europe, Canada, Japan and Australia. By 1961, the link was undeniable which led to 30 
the drug being removed from the market at the end of 1961 (Lenz and Knapp, 1962; 31 
McBride, 1961). 32 
 33 
The type of birth defects seen were severe and striking. Damage to multiple tissues 34 
and organs was seen including the eyes, ears, genitals, internal organs including 35 
gastrointestinal tract, facial nerves, heart and cardiovascular system as well as limbs 36 
(Kajii et al., 1973; Lenz and Knapp, 1962; McCredie and Willert, 1999; Smithells and 37 
Newman, 1992; Tajima et al., 2016). 38 
 39 
Thalidomide embryonic toxicity occurs in a short time window – now known as the 40 
time-sensitive window (day 20-36 post-conception) (Lenz, 1968; Vargesson, 2015). 41 
Several studies have since demonstrated that earlier embryonic exposure within this 42 
window causes more damage to multiple organ systems (Vargesson, 2013; 43 
Vargesson, 2015). It was reported that just a single 50mg tablet was enough to 44 
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damage the developing embryo/fetus and that 50% of pregnancies exposed to 45 
thalidomide resulted in affected children (Smithells and Newman, 1992).  46 
 47 
THALIDOMIDE – TODAY 48 
At present, it is known that thalidomide has multiple actions in the body, possessing 49 
anti-angiogenic, anti-inflammatory and immunomodulatory actions and is now used 50 
successfully to treat a wide range of clinical conditions including some cancers, 51 
multiple myeloma, erythema nodosum leprosum (ENL) (Franks et al., 2004; 52 
Vargesson, 2013; Vargesson, 2015). However, long term clinical use of thalidomide 53 
in the adult patient can cause the nasty side-effect, peripheral neuropathy 54 
(Vargesson, 2015). Furthermore, and tragically, a new generation of thalidomide 55 
survivors has also been seen in Brazil since 1996, which is due to the use of 56 
thalidomide to treat ENL and the medicine sharing culture that occurs in Brazil 57 
(Castilla et al., 1996; Vianna et al., 2011). This underlines how important it is to 58 
understand the complete mechanisms of action of thalidomide to try and make forms 59 
that retain clinical benefits without the side-effects of peripheral neuropathy and 60 
thalidomide-induced embryopathy. 61 
 62 
THALIDOMIDE-INDUCED LIMB DIFFERENCES 63 
Among the multiple effects of thalidomide, the most striking upon the embryo was to 64 
the limbs.  Upper limb deficiencies were more common and presentation ranged 65 
from triphalangeal thumb, to radial dysplasia (complete loss of radius and thumb and 66 
sometimes index finger), to phocomelia (severe shortening and/or loss of the 67 
proximal long bones whilst retaining parts of the distal hand/foot plate structures)  68 
and even amelia (Lenz and Knapp, 1962; McCredie and Willert, 1999; Newman, 69 
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1985; Newman, 1986; Smithells and Newman, 1992; Tajima et al., 2016). Multiple 70 
clinical studies have ascertained that some limb elements are more sensitive to 71 
thalidomide than others and an order of limb element loss can be determined, for 72 
example, the thumb is the most sensitive, followed by the radius, then the humerus, 73 
the ulna and finally fingers on the ulnar side (middle, ring and small) (Kajii et al., 74 
1973; Lenz and Knapp, 1962; McCredie and Willert, 1999; Newman, 1985; Newman, 75 
1986; Smithells and Newman, 1992). In the lower limb, when differences were 76 
present, the femur is the most commonly affected bone whereas the fibula the least 77 
affected bone (Lenz and Knapp, 1962; Smithells and Newman, 1992). Talipes was 78 
also seen in some thalidomide survivors and sometimes was the only damage to the 79 
lower limb (Smithells and Newman, 1992). In contrast to the upper limb, polydactyly 80 
of the toes was sometimes observed, usually presenting as duplication of the great 81 
toe (Smithells and Newman, 1992). The seemingly dual ability of thalidomide to 82 
cause both limb reduction and digit duplication within the same limb remains a 83 
mystery.   84 
 85 
Characteristic damage to the shoulder joint and pelvis is also observed in 86 
thalidomide embryopathy. Indeed, the acromioclavicular joint of the shoulder is much 87 
more prominent and ‘sharp’ in appearance (Smithells and Newman, 1992). The hip 88 
joint can be hypoplastic, or in some cases absent (Smithells and Newman, 1992). 89 
 90 
Limb differences are usually bilateral, although differences in the left limb is usually 91 
more severe than the right (Newman, 1985; Newman, 1986; Smithells and Newman, 92 
1992) and it remains unknown why one side would be more damaged than the other. 93 
Indeed, there are some reports of thalidomide exposed survivors with unilateral limb 94 
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anomalies, but these occurrences remain rare (Lenz and Knapp, 1962; Schmidt and 95 
Salzano, 1980). 96 
 97 
NORMAL LIMB DEVELOPMENT 98 
An understanding of normal embryonic limb development is needed in order to 99 
elucidate how thalidomide can cause limb differences. The upper limbs of the 100 
developing human embryo begin to form at day 26 post-fertilisation with the lower 101 
limbs following 1-2 days later (Vargesson and Hootnick, 2017). The limbs are first 102 
seen as buds or protrusions from the flank of the embryo and under the control of 103 
several signalling regions, the limb buds then grow out from the embryo body rapidly 104 
(Tabin and Wolpert, 2007; Vargesson, 2003). The major signalling centres 105 
controlling this outgrowth and subsequent patterning of all bony elements as well as 106 
support tissues are the Zone of Polarizing Activity (ZPA) and the Apical Ectodermal 107 
Ridge (AER) (Davey et al., 2018; Rodriguez-Niedenfuhr et al., 2001; Vargesson, 108 
2003). The ZPA situated in the posterior mesenchyme of the limb bud controls the 109 
anterior-posterior patterning of the limb, for example the formation and identification 110 
of the thumb to the small finger in the handplate and the radius and ulna in the 111 
forearm (Davey et al., 2018; Tabin and Wolpert, 2007; Tao et al., 2017; Vargesson, 112 
2003). The AER is involved in controlling and regulating proximal-distal outgrowth via 113 
the proliferation of cells in the limb bud. The ZPA and AER signal to and through 114 
each other to maintain outgrowth and patterning of the various tissues and elements. 115 
For example, the ZPA secretes Sonic hedgehog protein and the AER secretes 116 
fibroblast growth factor 8 which then signal to each other in a feedback loop, 117 
maintaining the respective pathways and at the same time, regulating the expression 118 
of many other genes involved in limb patterning (Tabin and Wolpert, 2007; Tao et al., 119 
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2017; Vargesson, 2003). The limb forms and differentiates in a time-dependent 120 
proximal to distal fashion, that is, the humerus/femur form before the radius/fibula 121 
and ulna/tibia which form before the digits (Davey et al., 2018; Tabin and Wolpert, 122 
2007; Tao et al., 2017; Vargesson, 2003. In order for limb development to occur 123 
normally, a variety of other tissues and processes are required, including a rapidly 124 
changing vasculature to permit the cell turnover and limb outgrowth as well as 125 
programmed cell death to shape the limb elements (Davey et al., 2018; Vargesson, 126 
2003). Precursors of the nerves and muscles enter the limb bud quite late in limb 127 
development, long after limb outgrowth has occurred (Mahony et al., 2018). In the 128 
human embryo, limbs are fully patterned by day 56 which is then followed by growth 129 
and maturation (Rodriguez-Niedenfuhr et al., 2001; Vargesson and Hootnick, 2017) 130 
(Figure 1A). 131 
 132 
MECHANISMS OF THALIDOMIDE TERATOGENESIS - MODELS 133 
Many models and theories have been proposed to explain the mechanism 134 
underlying the teratogenic actions of thalidomide. In fact, over 30 models have been 135 
proposed since the 1960s, including its effects on chrondrogenesis, DNA 136 
intercalation, nerve and neural crest damage, vitamin metabolism antagonism and 137 
effects on cell adhesion molecules (Stephens et al., 2000; Vargesson, 2013; 138 
Vargesson, 2015). While some of these can reasonably explain some of the 139 
damages seen in thalidomide survivors there remains continued debate about the 140 
precise mechanism of action, that explains all the damage, variability and time 141 
sensitive nature of thalidomide embryopathy.  142 
Current thinking favours thalidomide’s ability to bind cereblon and disrupt molecular 143 
signalling (Donovan et al., 2018; Ito et al., 2010; Matyskiela et al., 2018); inhibit 144 
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angiogenesis (D’Amato et al., 1994; Therapontos et al., 2009; Vargesson, 2009) and 145 
induce cell death and reactive oxygen species (Hansen and Harris, 2013; Knobloch 146 
et al., 2007). There remains the possibility that these three mechanisms are not 147 
mutually exclusive and together result in the damage. 148 
 149 
Cereblon (CRBN) Model 150 
CRBN is a direct binding partner of thalidomide (Ito et al., 2010). As a ubiquitin 151 
ligase, CRBN forms a complex to tag other signalling molecules for destruction. 152 
CRBN was identified as a target of thalidomide in a biochemical binding assay and 153 
when the protein was mutated to prevent thalidomide association, chicken and 154 
zebrafish embryos were unharmed following thalidomide exposure (Ito et al., 2010).  155 
However, precisely how CRBN binding to thalidomide results in thalidomide-induced 156 
limb damage and the variability between individuals in humans is still currently 157 
unexplained, although recent work is beginning to shed some light on this (Donovan 158 
et al., 2018; Matyskiela et al., 2018). 159 
 160 
Since the discovery of CRBN, a great deal of research has been focused on its role 161 
in mediating the role of thalidomide in adult conditions like myeloma (Ito and Handa, 162 
2016; Vargesson, 2015). This has led to the discovery that CRBN needs to recruit 163 
additional factors to the CRBN-thalidomide complex before resulting in specific 164 
actions. For example, in the treatment of myeloma, thalidomide binds CRBN which 165 
then recruits downstream proteins (IKAROS and AIOLOS) to successfully target 166 
myeloma cells (Chamberlain et al., 2014; Fischer et al., 2014; Ito and Handa, 2016). 167 
 168 
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Similarly, recent work demonstrates that following thalidomide binding, CRBN needs 169 
to target (and repress) another factor with important roles in embryonic development, 170 
namely SALL4, which is a transcription factor of the Spalt-like family (Donovan et al., 171 
2018; Matyskiela et al., 2018). The discovery of an interaction of thalidomide and 172 
cereblon with SALL4 is exciting because mutations in SALL4 are known to result in 173 
the following human conditions: Duane-Radial ray syndrome (DRRS), also known as 174 
Okihiro syndrome (Kohlhase and Holmes, 2004; Kohlhase et al., 2003); Acro-Renal-175 
Ocular syndrome (AROS) (Kohlhase et al., 2005) and the very rare IVIC syndrome, 176 
also known as Oculo-oto-radial syndrome (Paradisi and Arias, 2007). Together these 177 
conditions share many striking similarities with thalidomide embryopathy (TE) and 178 
indeed have been confused for TE previously and have also been termed 179 
thalidomide phenocopies (Kohlhase and Holmes, 2004; Kohlhase et al., 2003). 180 
These patients can present with a short humerus/radius/thumb deficiency, laterality 181 
differences where the reduction deficit differs between left and right limbs, as well as 182 
anomalies to the ears, eyes and internal organs. However, unlike TE, the legs are 183 
usually unaffected in these syndromes (Kohlhase et al., 2005; Kohlhase and 184 
Holmes, 2004; Kohlhase et al., 2003; Smithells and Newman, 1992).   185 
 186 
Additional evidence supporting a role for CRBN in TE comes from studies 187 
demonstrating that the teratogenic enantiomer of thalidomide binds CRBN but the 188 
sedative enantiomer does not (Mori et al., 2018). Thalidomide has the ability to 189 
switch between two enantiomer forms in body fluids (Franks et al., 2004; Vargesson, 190 
2013). There are also species differences in CRBN activity, such that thalidomide-191 
sensitive species can bind CRBN and degrade substrates, whereas mice and rats 192 
which are thalidomide-insensitive though possessing CRBN have structural changes 193 
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resulting in the failure of degradation (Kronke et al., 2015). Moreover, the ability of 194 
the thalidomide/cereblon complex to bind to and inhibit SALL4 is also species-195 
specific and only occurs in thalidomide-sensitive species (Donovan et al., 2018; 196 
Matyskiela et al., 2018). This could explain the famous species-specific effects of the 197 
drug, where mouse and rat embryos are insensitive to the teratogenic actions of the 198 
drug (Vargesson, 2013; Vargesson, 2015).  199 
 200 
The discovery of SALL4 as a target of the thalidomide-cereblon complex is exciting, 201 
and in many respects, makes sense, given the similarity in upper limb differences 202 
and some other tissue malformations between thalidomide embryopathy and DRRS, 203 
AROS and IVC. Moreover, SALL4 has been previously been proposed to be a target 204 
of thalidomide (Knobloch and Ruther, 2008; Kohlhase et al., 2003; Kohlhase et al., 205 
2005). However, whether this molecular interaction with thalidomide causes all the 206 
tissue malformations and changes seen in thalidomide embryopathy is yet to be fully 207 
demonstrated. In addition, just how this molecular interaction results in the actual 208 
tissue malformations is also unclear. Furthermore, DRRS, AROS and IVIC affects 209 
the upper limbs and not usually the lower limbs, which can also be affected in TE 210 
(Kohlhase et al., 2005; Kohlhase and Holmes, 2004; Kohlhase et al., 2003; Smithells 211 
and Newman, 1992). This suggests that there may be other targets of CRBN, 212 
perhaps tissue specific or indeed there may be other binding partners or actions of 213 
thalidomide.  214 
 215 
Indeed, many other molecular targets of thalidomide have been proposed previously 216 
(Vargesson, 2015); for example, several genetic screens in embryonic stem cells 217 
and animal (non-human primate) embryos following thalidomide exposure show 218 
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thousands of gene expression profile changes, and CRBN is not identified in many of 219 
these (Ema et al., 2010; Meganathan et al., 2012).  220 
 221 
Anti-angiogenesis Model 222 
A separate (but likely inter-related) theory is through the ability of thalidomide to 223 
prevent and destroy blood vessel formation (anti-angiogenesis) (Vargesson, 2013; 224 
Vargesson, 2015). Thalidomide was first shown to be anti-angiogenic in rabbit and 225 
rodent cornea assays in the 1990’s (D'Amato et al., 1994; Kenyon et al., 1997). Yet, 226 
experimental evidence from chicken embryos suggested effects on limb vasculature 227 
several decades earlier  (Jurand, 1966). Since these findings, the anti-angiogenic 228 
roles of thalidomide have been used in adults successfully to treat conditions 229 
including hereditary hemorrhagic telangiectasia (HHT), diabetic retinopathy and 230 
some cancers, through the prevention of vessel leakage and also by suppressing 231 
angiogenesis (Lebrin et al., 2010).  232 
 233 
Such a mechanism has been experimentally demonstrated to explain the range, 234 
occurrence of damage, the timing as well as the global nature of the drugs action. 235 
For example, an anti-angiogenic analogue of thalidomide, called CPS49, was shown 236 
to be able to induce, in a time-sensitive manner, a range of damages including 237 
phocomelia-like limbs, radial dysplasia and other anomalies (Davey et al., 2018; 238 
Therapontos et al., 2009). CPS49 was demonstrated to affect newly formed or newly 239 
forming vessels only (Therapontos et al., 2009). These effects were rapid and occur 240 
before changes were seen in expression patterns of important limb development 241 
genes and followed by the induction of cell death (Therapontos et al., 2009; 242 
Vargesson, 2009). Furthermore, vessel loss and its effects upon the limb occurs 243 
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before nerve innervation of the limbs (Mahony et al., 2018). Moreover, nerve 244 
inhibition before and during limb outgrowth does not cause thalidomide-like limb 245 
damage (Mahony et al., 2018). 246 
 247 
Several other studies have demonstrated thalidomide induces vessel loss and/or 248 
haemorrhages in embryos (Jurand, 1966; Knobloch et al., 2007; Sorensen et al., 249 
2017; Tamilarasan et al., 2006). We also know that thalidomide survivors themselves 250 
exhibit a wide range of cardiovascular changes including heart defects, some of 251 
which might actually contribute to the differences seen in thalidomide survivors 252 
(Tajima et al., 2016; see also Vargesson and Hootnick, 2017). In further support of 253 
this mechanism, multiple anti-angiogenic drugs used as anti-cancer agents, for 254 
example sunitinib and sorafenib (Beedie et al., 2016a), which induce cell death, have 255 
a wide range of molecular targets and all of these can cause limb damage (Beedie et 256 
al., 2016a; Beedie et al., 2017). This indicates that vessel inhibition is a key element 257 
underlying drug-induced limb defects.  258 
 259 
Blood vessels are essential for cells and tissues to be supplied by nutrients and to 260 
remove waste products (Vargesson, 2003). The limbs develop rapidly and undergo 261 
major changes almost continuously and as a result require a rapidly changing 262 
vasculature to accommodate development, growth and differentiation (Vargesson, 263 
2003; Vargesson and Hootnick, 2017).  Around the fifth to sixth week of human 264 
embryonic development, cartilage condensations begin forming in the limbs, with the 265 
proximal elements condensing before the more distal element and as they do the 266 
local vessels must regress (Rodriguez-Niedenfuhr et al., 2001; Vargesson and 267 
Hootnick, 2017). The cartilage condensations begin to form bone from the sixth and 268 
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seventh weeks, and require vascularization to allow the process to continue through 269 
nourishment and to maintain the chrondrified bone (Rodriguez-Niedenfuhr et al., 270 
2001; Vargesson and Hootnick, 2017). Different bony elements have different 271 
amounts of vascularization, for example, the ulna has several arterial supplies (ulnar 272 
and median artery), yet the radius has one, the radial artery  (Vargesson and 273 
Hootnick, 2017). Thus, the radius is more sensitive to vascular injury than the ulna 274 
and this might explain why in some thalidomide survivors the radius is missing but 275 
the ulna remains. 276 
 277 
At the time the cartilage condensations are appearing, the vascular pattern in the 278 
developing limb undergoes a transition from the embryonic state to the final adult 279 
pattern by the end of the seventh week of development (Figure 2; Vargesson and 280 
Hootnick, 2017). This has led to suggestions that limb malformations may arise from 281 
injury or failure to transit to the adult pattern which normally permits the correct 282 
vascularization for forming bony elements and limb formation (Vargesson and 283 
Hootnick, 2017). Indeed, there is evidence that limb differences in human foetuses 284 
have missing or misplaced vessels (Hoyme et al., 1982; Van Allen et al., 1982; 285 
Vargesson and Hootnick, 2017). For example, in limbs with radial dysplasia, the 286 
radial artery is malpositioned and has been alleged to be the cause of the bony loss 287 
(Hoyme et al., 1982; Van Allen et al., 1982). Finally, Holt-Oram syndrome patients 288 
exhibiting limb reduction anomalies (which can be confused with TE) have a 289 
significantly reduced peripheral vasculature; indeed, it may be difficult to discern a 290 
palpable pulse in such patients (DuPre and Fincher, 1993), a characteristic often 291 
demonstrated in the limbs in thalidomide survivors (Smithells and Newman, 1992; 292 
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Tajima et al., 2016). Thus, thalidomide-induced inhibition of vessel formation could 293 
result in the tissue differences in the limbs.  294 
 295 
Cell death and reactive oxygen species induction model 296 
Thalidomide has the ability to induce reactive oxygen species in tissues (which can 297 
damage and harm tissues) and cell death in embryonic limbs (Hansen and Harris, 298 
2013; Knobloch et al., 2007). When reactive oxygen species are prevented from 299 
being pharmacologically induced, embryos are no longer damaged by thalidomide 300 
when directly exposed to the drug (Hansen and Harris, 2013). Precisely how reactive 301 
oxygen species and cell death is induced by thalidomide in specific tissues and 302 
bones and not all cells remains unclear. 303 
 304 
In summary, when taken together, the different mechanisms that have been 305 
proposed and outlined herein are likely inter-related for the explanation of 306 
thalidomide-induced limb differences. The destruction of vessels leading to 307 
subsequent localised induction of cell death in tissues can explain the occurrence, 308 
range and timing of thalidomide-induced limb defects. However, given thalidomide’s 309 
species sensitivity, where pregnant rodents embryos are insensitive to thalidomide, 310 
this indicates that there must be species-specific mechanisms or molecular target/s, 311 
for example, CRBN, which then triggers the cascade of events, including effects on 312 
blood vessels and cell death induction, to result in the actual tissue damage.  313 
 314 
 315 
CURRENT UNDERSTANDING OF THE MECHANISM OF THALIDOMIDE-316 
INDUCED LIMB TERATOGENESIS 317 
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 318 
As mentioned, recent work that suggests thalidomide interacts with the molecular 319 
target CRBN to repress SALL4 to cause thalidomide phenocopies such as   DRRS, 320 
AGOS and IVIC in embryos (Donovan et al., 2018; Matyskiela et al., 2018) is 321 
exciting, although presently how this interaction results in the actual tissue 322 
differences remains unclear. In addition, whether this molecular interaction is 323 
responsible for all the tissue malformations induced by thalidomide in the embryo 324 
also remains to be determined. Another binding target of CRBN was recently 325 
identified, argonaute2 (AGO2) (Xu et al., 2016). This molecule has roles in 326 
angiogenesis suggesting that CRBN’s interaction with thalidomide could also 327 
influence angiogenesis via AGO2, further suggesting CRBN may have multiple 328 
downstream targets, and that the precise molecular pathway/s require further 329 
elucidation. 330 
 331 
Limb differences likely result from downstream events such as vessel loss/inhibition 332 
which disrupts the embryonic to adult vascular transition, induction of localised cell 333 
death resulting in disruption of normal molecular signalling in the limb and ultimately 334 
in tissue loss or further malformation of tissues (Figure 3). As the effect of 335 
thalidomide wears off (half-life 8-12hr; Franks et al., 2004), the limb tries to recover 336 
and re-establish the normal signalling and morphogenetic events. Condensations of 337 
cartilage cells will attempt to form, and depending on the extent of tissue loss may be 338 
shorter or may not form at all. They will then be vascularised by surviving vessels, 339 
assuming they are present, resulting in smaller limbs and specific bone loss. The 340 
damage is then further exacerbated by secondary cell induction changes; nerves 341 
and muscle cells migrate into the limb but as the limb tissue is either not there or not 342 
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in the correct place, nerves and muscles are misplaced, thus exacerbating further 343 
damage (Therapontos et al., 2009; Vargesson, 2009) (Figure 1B; Figure 3).  344 
 345 
THE FUTURE 346 
Understanding precisely how thalidomide causes embryonic malformation could help 347 
shed light on how congenital conditions like DRRS, AGOS and IVC come about and 348 
is key to understanding if clinically relevant versions of the drug, without the spectre 349 
of causing birth defects, can ever be made. This is especially relevant today in 350 
countries like Brazil, where the accidental use of thalidomide by pregnant women 351 
when treating complications of leprosy has led to a new generation of thalidomide 352 
survivors. Encouragingly, some inroads have been made through the production of 353 
structural analogs without anti-angiogenic actions (Beedie et al., 2016b).  354 
 355 
With the greatly renewed interest in thalidomide for adult treatments and the revived 356 
interest in the teratogenic mechanisms, it must only be a matter of time before we 357 
finally uncover the precise mechanism(s) of the drug. 358 
  359 
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 360 
FIGURE LEGENDS 361 
Figure 1 – Limb development and model of how thalidomide affects limb 362 
development 363 
A. Normal limb development and outgrowth is regulated by the apical ectodermal 364 
ridge (AER) and zone of polarizing activity (ZPA), maintaining outgrowth and 365 
gene expression resulting in the final, normal adult pattern. 366 
B. Thalidomide inhibits angiogenesis resulting in cell death and loss of signalling 367 
between the AER and ZPA. Prolonged exposure results in amelia (no limb or 368 
a rudiment of bone); short exposure results in temporary loss of signalling 369 
pathway loss, which recovers to allow remaining cells to be patterned, as 370 
these cells are near the AER they will be distal at the expense of proximal 371 
cells, resulting in phocomelia. 372 
Figure reproduced with permission from (Vargesson, 2015). 373 
 374 
Figure 2 – Vascular transition 375 
During human limb development a transition from the embryonic capillary 376 
network to the adult pattern occurs between weeks 5 and 7. Figure 377 
reproduced with permission from (Rodriguez-Niedenfuhr et al., 2001). 378 
 379 
Figure 3 – Framework of thalidomide induced embryonic damage  380 
Reproduced with modifications and permission from (Vargesson, 2015). 381 
 382 
 383 
 384 
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